✦ LIBER ✦

Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells

✍ Scribed by Kitazaki, Takeshi; Oka, Mikio; Nakamura, Yoichi; Tsurutani, Junji; Doi, Seiji; Yasunaga, Masa; Takemura, Masaaki; Yabuuchi, Hikaru; Soda, Hiroshi; Kohno, Shigeru

Book ID: 119319213
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 249 KB
Volume: 49
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2005.03.035

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

AZD3409 inhibits the growth of breast ca

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

✍ Monica R. Maiello; Amelia D’Alessio; Antonella De Luca; Adele Carotenuto; Anna M 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 290 KB

The MEK/MAPK pathway is involved in the

The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

✍ Nicola Normanno; Antonella De Luca; Monica R. Maiello; Manuela Campiglio; Maria 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB 👁 1 views

## Abstract We investigated the role of the MEK/MAPK pathway in the sensitivity/resistance of breast carcinoma cells to the EGFR tyrosine kinase inhibitor gefitinib (IRESSA). We assessed the effects of gefitinib on the growth of three breast cancer cell lines that showed high (SK‐Br‐3; IC~50~ 4 µM)

Breast cancer cells with acquired resist

Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling

✍ Nicola Normanno; Manuela Campiglio; Monica R. Maiello; Antonella De Luca; Mario 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 408 KB

ZD1839 (IRESSA), an EGFR-selective tyros

ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells

✍ Fortunato Ciardiello; Rosa Caputo; Gaetano Borriello; Donatella Del Bufalo; Anna 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 339 KB

## Abstract Constitutive bcl‐2 overexpression increases the tumorigenic and metastatic potential of doxorubicin‐resistant, estrogen‐independent, MCF‐7 ADR human breast cancer cells. We evaluated the sensitivity to taxanes (paclitaxel, docetaxel and IDN 5109) of 2 bcl‐2‐overexpressing MCF‐7 ADR clon

Gefitinib (‘Iressa’), an epidermal growt

Gefitinib (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells

✍ Satoru Shintani; Chunnan Li; Mariko Mihara; Koh-ichi Nakashiro; Hiroyuki Hamakaw 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 239 KB

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell